Botanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s announcement that it had appointed executives, Howie McKibbon, Chief Commercial Officer (CCO) and Dr Patricia Walker, Chief Medical Officer (CMO).
Botanix has today welcomed two highly experienced US-based dermatology executives to the team:
Dr Walker is a board-certified dermatologist specialising in medical and aesthetic dermatology. She is an industry expert and has served in various leadership roles, including President and head of R&D for Brickell Biotech; Chief Medical Officer for Kythera Biopharmaceuticals, Inc.; Executive Vice President and Chief Scientific Officer for Allergan Medical Aesthetics; and Vice President and Dermatology Therapeutic Area Head at Allergan.
Howie has more than 20 years of leadership experience in the pharmaceutical industry, including working directly as part of my team as Senior-Vice President, Sales and Marketing at Anacor Pharmaceuticals; Senior Vice-President, Worldwide Commercial Operations at Dermavant Science; and Vice-President, Dermatology and Immunology at Medicis Pharmaceuticals. Howie has launched 15 products including 11 in dermatology, and managed over 30 dermatology products. Importantly too, he played a significant role in two of the world’s largest dermatology acquisitions with combined valuations of $7.8 billion.
These new executives contribute valuable dermatology and commercial leadership credentials to our team, as Botanix prepares to move from clinical development towards focused commercialisation of our product portfolio.
Botanix (ASX:BOT) is pleased to share a Quick Comment research report from leading stockbroking firm, Euroz Hartleys, following the Company’s announcement that it had received an R&D tax incentive refund of $2.75m.
Botanix Executive Director, Matt Callahan, visited Melbourne last week and took the time to participate in a boardroom interview with veteran business and biotech journalist, @Tim Boreham.
As part of this conversation, Matt Callahan explains the strategic importance of following the US Food and Drug Administration’s (FDA) clinical development blueprint, as we develop our dermatology and antimicrobial products, and reiterates the value of recruiting a highly experienced team at the helm.
He also explains the meticulous methodology underpinning Botanix’s clinical trial process and how we are moving our late-stage products even closer to large underserved patient cohorts in the world’s largest healthcare markets.
Take a look:
Botanix has today announced the appointment of a new Australian-based Non-Executive Director to the Board, Danny Sharp.
Danny is a highly respected investment banker with more than 30 years’ experience and strong networks within global capital markets, institutional investment and private wealth too. Healthcare and technology are his speciality areas of expertise.
Most recently, Danny was Corporate Finance Executive Director of Canaccord Genuity, and he has previously spearheaded the Corporate Finance departments at both Shaw and Partners and Lodge Partners.
Interested to learn more about the opportunities we are pursuing at Botanix, directly from the people at the centre of our clinical development work?
Over the next two months we’ll be sharing with you a Conversation Series, showcasing video interviews with specialist consultants and key opinion leaders who we are proud to have recruited to our leadership team.
The first of these is with Dr Ira Lawrence, a Medical Advisor with more than 30 years of senior leadership experience within the global pharmaceutical and medical device industries.
Watch this short video to hear what Dr Lawrence has to say about the future of dermatology.
Botanix (ASX:BOT) is pleased to share a Quick Comment research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s December quarterly update.
Analyst Seth Lizee commented:
“The company is looking to shake up big markets in dermatology and antimicrobials with its four clinical programs. The prize, should individual programs ultimately be clinically successful, is huge.”
Botanix Executive Director, Matt Callahan, recently participated in the ShareCafe Small Cap ‘Hidden Gems’ Webinar.
His presentation provided an overview of our clinical pipeline, including the significant potential for new dermatology products and opportunities for adding new assets to our pipeline. Matt also shared an update on upcoming clinical and operational milestones for 2022.
Botanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s December quarterly report.
2022 is described as “a big year ahead”.
Botanix (ASX:BOT) has today published its Quarterly Activities Report and 4C Quarterly Cash Flow Report, for the period ended 31 December 2021.
Key highlights from this period include:
Botanix’s balance sheet remains strong, with $16.8 million in cash at closing of 4Q 2021 with R&D tax return to come this quarter.
